BioTime and OncoCyte Corporation Publish Data on the Gene as a Marker and Potential Diagnostic for a Wide Array of Human Cancers BioTime, Inc.Peter Garcia, 510-521-3390 ext. 367Chief Financial ...
New Release Features “Super-Pathways” and Collaboration with Lost Island Labs, Inc. <0> BioTime, Inc.Peter Garcia, 510-521-3390, ext. 367Chief Financial OfficerJudith Segall, 510-521-3390, ext.
On August 2, 2018, BioTime Inc. (NYSE: BTX; $2.31; market capitalization: $293 million) announced results for 2Q18. BioTime primary clinical programs Renevia and OpRegen progressed on research and ...
Alameda-based BioTime, which has seen its stock double in the past year, reached an agreement this week to provide important embryonic stem cell lines to California-based researchers for free in hopes ...
In an effort to make stem cell treatments more viable in the field of regenerative medicine, BioTime ($BTX) has developed a delivery system designed to mimic the ...
MENLO PARK, Calif. & ALAMEDA, Calif.--(BUSINESS WIRE)--Asterias Biotherapeutics, Inc. and BioTime, Inc. (NYSE MKT: BTX) jointly announced today the closing of the transactions under the Asset ...
ALAMEDA, Calif. & MENLO PARK, Calif.--BioTime, Inc. (NYSE MKT: BTX) announced today that its subsidiary Asterias Biotherapeutics, Inc. ("Asterias"), has raised $12.5 million through the sale of ...
BioTime announced the results of its capital raising activities since October 1, 2013 through its $25M Controlled Equity Offering facility, and through sales of BioTime common shares by certain of its ...
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that on May 1, 2014, the Company received approximately ...
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has closed the previously ...